Axonal ion channel dysfunction in C9orf72 familial amyotrophic lateral sclerosis

JAMA Neurology

Volumn 72, Issue 1, 2015, Pages 49-57

  Geevasinga, Nimeshan ^a   Menon, Parvathi ^a   Howells, James ^b   Nicholson, Garth A ^b   Kiernan, Matthew C ^b   Vucic, Steve ^a  

^a University of Sydney   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM CHANNEL; SODIUM CHANNEL; C9ORF72 PROTEIN, HUMAN; ION CHANNEL; PROTEIN;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; C9ORF72 GENE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FAMILIAL DISEASE; FEMALE; GENE; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; MALE; MUSCLE WEAKNESS; NERVE EXCITABILITY; PATHOGENESIS; PHENOTYPE; POTASSIUM CHANNELOPATHY; PROSPECTIVE STUDY; SODIUM CHANNELOPATHY; SPORADIC AMYOTROPHIC LATERAL SCLEROSIS; UPREGULATION; ACTION POTENTIAL; CLINICAL TRIAL; ELECTROSTIMULATION; GENETICS; INNERVATION; MEDIAN NERVE; MIDDLE AGED; MULTICENTER STUDY; MUTATION; NERVE FIBER; PATHOPHYSIOLOGY; PHYSIOLOGY; THEORETICAL MODEL; WRIST; YOUNG ADULT;

ACTION POTENTIALS; ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; AXONS; COHORT STUDIES; ELECTRIC STIMULATION; FEMALE; HUMANS; ION CHANNELS; MALE; MEDIAN NERVE; MIDDLE AGED; MODELS, THEORETICAL; MUTATION; PROSPECTIVE STUDIES; PROTEINS; WRIST; YOUNG ADULT;

EID: 84921038530     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.2940     Document Type: Article

References (62)

1. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377 (9769):942-955.
2. Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol. 2011;7(11):603-615.
3. Renton AE, Majounie E, Waite A, et al; ITALSGEN Consortium. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257-268.
4. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245-256.
5. Majounie E, Renton AE, Mok K, et al; Chromosome 9-ALS/FTD Consortium; French research network on FTLD/FTLD/ALS; ITALSGEN Consortium. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11(4):323-330.
6. Snowden JS, Harris J, Richardson A, et al. Frontotemporal dementia with amyotrophic lateral sclerosis: a clinical comparison of patients with and without repeat expansions in C9orf72. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(3): 172-176.
7. Williams KL, Fifita JA, Vucic S, et al. Pathophysiological insights into ALS with C9ORF72 expansions. J Neurol Neurosurg Psychiatry. 2013;84 (8):931-935.
8. van Rheenen W, van Blitterswijk M, Huisman MH, et al. Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases. Neurology. 2012;79(9):878-882.
9. Vucic S, Kiernan MC. Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol. 2006;117(7):1458-1466.
10. Kanai K, Kuwabara S, Misawa S, et al. Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage. Brain. 2006;129(pt 4):953-962.
11. Nakata M, Kuwabara S, Kanai K, et al. Distal excitability changes in motor axons in amyotrophic lateral sclerosis. Clin Neurophysiol. 2006;117(7): 1444-1448.
12. + currents in human neuropathy and motor neuron disease estimated by latent addition. Clin Neurophysiol. 2006;117(11):2451-2458.
13. Bostock H, Sharief MK, Reid G, Murray NM. Axonal ion channel dysfunction in amyotrophic lateral sclerosis. Brain. 1995;118(pt 1):217-225.
14. Horn S, Quasthoff S, Grafe P, Bostock H, Renner R, Schrank B. Abnormal axonal inward rectification in diabetic neuropathy. Muscle Nerve. 1996;19 (10):1268-1275.
15. Mogyoros I, Kiernan MC, Burke D, Bostock H. Strength-duration properties of sensory and motor axons in amyotrophic lateral sclerosis. Brain. 1998; 121(pt 5):851-859.
16. Kiernan M, Burke D. Threshold electrotonus and the assessment of nerve excitability in amyotrophic lateral sclerosis. In: Eisen A, ed. Clinical Neurophysiology of Motor Neuron Diseases. Amsterdam, the Netherlands: Elsevier; 2004:359-366.
17. Menon P, Kiernan MC, Vucic S. ALS pathophysiology: insights from the split-hand phenomenon. Clin Neurophysiol. 2014;125(1):186-193.
18. Shibuya K, Misawa S, Nasu S, et al. Split hand syndrome in amyotrophic lateral sclerosis: different excitability changes in the thenar and hypothenar motor axons. J Neurol Neurosurg Psychiatry. 2013; 84(9):969-972.
19. Kanai K, Kuwabara S, Arai K, Sung JY, Ogawara K, Hattori T. Muscle cramp in Machado-Joseph disease: altered motor axonal excitability properties and mexiletine treatment. Brain. 2003;126(pt 4):965-973.
20. Kiernan MC, Bostock H. Effects of membrane polarization and ischaemia on the excitability properties of human motor axons. Brain. 2000;123 (pt 12):2542-2551.
21. Kiernan MC, Burke D, Andersen KV, Bostock H. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve. 2000;23 (3):399-409.
22. Krishnan AV, Lin CS, Park SB, Kiernan MC. Axonal ion channels from bench to bedside: a translational neuroscience perspective. Prog Neurobiol. 2009;89(3):288-313.
23. Bostock H. The strength-duration relationship for excitation ofmyelinated nerve: computed dependence on membrane parameters. J Physiol. 1983;341:59-74.
24. Bostock H, Rothwell JC. Latent addition in motor and sensory fibres of human peripheral nerve. J Physiol. 1997;498(pt 1):277-294.
25. Mogyoros I, Kiernan MC, Burke D. Strength-duration properties of human peripheral nerve. Brain. 1996;119(pt 2):439-447.
26. Mogyoros I, Kiernan MC, Burke D. Strength-duration properties of sensory and motor axons in carpal tunnel syndrome. Muscle Nerve. 1997;20(4):508-510.
27. Mogyoros I, Lin CS, Kuwabara S, Cappelen-Smith C, Burke D. Strength-duration properties and their voltage dependence as measures of a threshold conductance at the node of Ranvier of single motor axons. Muscle Nerve. 2000;23(11):1719-1726.
28. Burke D, Kiernan MC, Bostock H. Excitability of human axons. Clin Neurophysiol. 2001;112(9):1575-1585.
29. Cedarbaum JM, Stambler N, Malta E, et al; BDNF ALS Study Group (Phase III). The ALSFRS-R: a revised ALS Functional Rating Scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169(1-2):13-21.
30. Medical Research Council. Aid to the Examination of the Peripheral Nervous System. London, England: Her Majesty's Stationary Office; 1976.
31. Turner MR, Cagnin A, Turkheimer FE, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004;15(3):601-609.
32. Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry. 2006;21(11):1078-1085.
33. de Carvalho M, Swash M. Nerve conduction studies in amyotrophic lateral sclerosis. Muscle Nerve. 2000;23(3):344-352.
34. Bostock H, Cikurel K, Burke D. Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve. 1998;21(2):137-158.
35. Weiss G. Sur la possibilité de rendre comparables entre eux les appareils servant l'excitation électrique. Arch Ital Biol. 1901;35:413-446.
36. Kiernan MC, Lin CS, Andersen KV, Murray NM, Bostock H. Clinical evaluation of excitability measures in sensory nerve. Muscle Nerve. 2001;24(7):883-892.
37. Farrar MA, Vucic S, Lin CS, et al. Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy. Brain. 2011;134(pt 11):3185-3197.
38. Kiernan MC, Isbister GK, Lin CS, Burke D, Bostock H. Acute tetrodotoxin-induced neurotoxicity after ingestion of puffer fish. Ann Neurol. 2005;57(3):339-348.
39. Bostock H, Baker M, Reid G. Changes in excitability of human motor axons underlying post-ischaemic fasciculations: evidence for two stable states. J Physiol. 1991;441:537-557.
40. Farrar MA, Park SB, Lin CS-Y, Kiernan MC. Evolution of peripheral nerve function in humans:novel insights from motor nerve excitability. J Physiol. 2013;591(pt 1):273-286.
41. Schwarz JR, Reid G, Bostock H. Action potentials and membrane currents in the human node of Ranvier. Pflugers Arch. 1995;430(2):283-292.
42. Howells J, Trevillion L, Bostock H, Burke D. The voltage dependence of I(h) in human myelinated axons. J Physiol. 2012;590(pt 7):1625-1640.
43. Kiernan MC, Cikurel K, Bostock H. Effects of temperature on the excitability properties of human motor axons. Brain. 2001;124(pt 4):816-825.
44. Eisen A. Clinical electrophysiology of the upper and lower motor neuron in amyotrophic lateral sclerosis. Semin Neurol. 2001;21(2):141-154.
45. Mogyoros I, Lin C, Dowla S, Grosskreutz J, Burke D. Strength-duration properties and their voltage dependence at different sites along the median nerve. Clin Neurophysiol. 1999;110(9):1618-1624.
46. Baker MD, Bostock H. Low-threshold, persistent sodium current in rat large dorsal root ganglion neurons in culture. J Neurophysiol. 1997;77(3):1503-1513.
47. Nakata M, Baba H, Kanai K, et al. Changes in Na(+) channel expression and nodal persistent Na(+)currents associated with peripheral nerve regeneration in mice. Muscle Nerve. 2008;37(6):721-730.
48. Vucic S, Kiernan MC. Upregulation of persistent sodium conductances in familial ALS. J Neurol Neurosurg Psychiatry. 2010;81(2):222-227.
49. Wainger BJ, Kiskinis E, Mellin C, et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 2014;7(1):1-11.
50. Cheah BC, Lin CSY, Park SB, Vucic S, Krishnan AV, Kiernan MC. Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clin Neurophysiol. 2012;123(12):2460-2467.
51. Kanai K, Shibuya K, Sato Y, et al. Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(7):734-738.
52. Stys PK. Anoxic and ischemic injury of myelinated axons in CNS white matter: from mechanistic concepts to therapeutics. J Cereb Blood Flow Metab. 1998;18(1):2-25.
53. Stys PK. Axonal degeneration in multiple sclerosis: is it time for neuroprotective strategies? Ann Neurol. 2004;55(5):601-603.
54. Stys PK. General mechanisms of axonal damage and its prevention. J Neurol Sci. 2005;233(1-2):3-13.
55. Stys PK. Sodium channel blockers as neuroprotectants in neuroinflammatory disease: a double-edged sword. Ann Neurol. 2007;62(1):3-5.
56. Waxman SG. Axonal conduction and injury in multiple sclerosis: the role of sodium channels. Nat Rev Neurosci. 2006;7(12):932-941.
57. Roth G. The origin of fasciculations. Ann Neurol. 1982;12(6):542-547.
58. Roth G. Fasciculations and their F-response.Localisation of their axonal origin. J Neurol Sci. 1984;63(3):299-306.
59. Mills KR. Characteristics of fasciculations in amyotrophic lateral sclerosis and the benign fasciculation syndrome. Brain. 2010;133(11):3458-3469.
60. de Carvalho M, Swash M. Fasciculation potentials and earliest changes in motor unit physiology in ALS. J Neurol Neurosurg Psychiatry. 2013;84(9):963-968.
61. de Carvalho M, Swash M. Cramps, muscle pain, and fasciculations: not always benign? Neurology. 2004;63(4):721-723.
62. Gubbay SS, Kahana E, Zilber N, Cooper G, Pintov S, Leibowitz Y. Amyotrophic lateral sclerosis: a study of its presentation and prognosis. J Neurol. 1985;232(5):295-300.